The following letter was issued concerning the WannaCry ransomware attack in May 2017. The directions provided to protect your system also apply to the June 2017 Petya ransomware attack.
Asia
Europe, Middle East, Africa
North America
Product Security Notice
28 June, 2017
Independence Day Holiday Shipping Schedule
14 June, 2017
Please be advised the bioMérieux manufacturing and shipping locations in Durham, NC, St. Louis, MO, Louisville, KY and Lombard, IL will be closed on Tuesday, July 4, 2017 in observance of Independence Day.
bioMérieux receives FDA Clearance for BioFire’s FilmArray® Respiratory Panel 2 (RP2)
01 June, 2017
The FilmArray® RP2 reduces sample-to-result time to only 45 minutes while enhancing pathogen coverage and overall sensitivity
bioMérieux supporting the launch of the AMR Industry Alliance
22 May, 2017
Marcy l'Etoile, France, May 2017 - Media Statement - bioMérieux, a world leader in the field of in vitro diagnostics, is pleased to support the launch of the AMR Industry Alliance, a new alliance to drive and measure industry progress to curb antimicrobial resistance.
With New Instrument and Assay Claims, BioMérieux Takes on Antibiotic Stewardship
11 May, 2017
With a recently approved blood culture system, new indications for its procalcitonin (PCT) diagnostic assay, and an arsenal of molecular testing tools, bioMérieux is aiming to become a leader in the increasingly competitive field of antibiotic stewardship.
Sepsis Alliance and bioMérieux, Inc. Expand Partnership for 2017 to Promote Sepsis Awareness and Prevention
10 May, 2017
Durham, NC – San Diego, CA (May 10, 2017) – bioMérieux, a world leader in the field of in vitro diagnostics, is proud to announce that its U.S. affiliate, bioMérieux Inc. will be expanding its partnership with Sepsis Alliance. bioMérieux Inc. will serve as the 2017 National Sepsis Awareness and Education Title Sponsor, including sponsorship of Sepsis Alliance’s Sepsis Challenge™ events.
bioMérieux 2016 Annual Report
10 May, 2017
A world leader in the field of in vitro diagnostics for over 50 years, bioMérieux is present in more than 150 countries through 42 subsidiaries and a large network of distributors. In 2016, revenues reached €2,103 million, with more than 90% of international sales.
The war against superbugs starts here in North Carolina
08 May, 2017
Nearly every day, there are new reports of antibiotic resistance bacteria – superbugs – that are becoming more difficult to treat. Early this year, the Centers for Disease Control and Prevention reported on the death of a woman in Nevada who had a resistant bacterial infection that was impervious to 26 different antibiotic drugs.
bioMérieux – First-Quarter 2017 Business Review
20 April, 2017
Marcy l'Étoile (France), April 20, 2017 – bioMérieux, a world leader in the field of in vitro diagnostics, today released its business review for the three months ended March 31, 2017.
bioMérieux receives FDA 510(k) clearance for its BacT/ALERT® VIRTUO™ fully automated blood culture system
06 April, 2017
Marcy l’Étoile (France) - April 6, 2017 – bioMérieux, a major player in the field of in vitro diagnostics, and the world leader in microbiology, announces that BacT/ALERT® VIRTUO™, its fully automated blood culture system, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).